Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Serena Cecchetti is active.

Publication


Featured researches published by Serena Cecchetti.


Nature Genetics | 2009

Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair

Viviana Cordeddu; Elia Di Schiavi; Len A. Pennacchio; Avi Ma'ayan; Anna Sarkozy; Valentina Fodale; Serena Cecchetti; Alessio Cardinale; Joel Martin; Wendy Schackwitz; Anna Lipzen; Giuseppe Zampino; Laura Mazzanti; Maria Cristina Digilio; Simone Martinelli; Elisabetta Flex; Francesca Lepri; Deborah Bartholdi; Kerstin Kutsche; Giovanni Battista Ferrero; Cecilia Anichini; Angelo Selicorni; Cesare Rossi; Romano Tenconi; Martin Zenker; Daniela Merlo; Bruno Dallapiccola; Ravi Iyengar; Paolo Bazzicalupo; Bruce D. Gelb

N-myristoylation is a common form of co-translational protein fatty acylation resulting from the attachment of myristate to a required N-terminal glycine residue. We show that aberrantly acquired N-myristoylation of SHOC2, a leucine-rich repeat–containing protein that positively modulates RAS-MAPK signal flow, underlies a clinically distinctive condition of the neuro-cardio-facial-cutaneous disorders family. Twenty-five subjects with a relatively consistent phenotype previously termed Noonan-like syndrome with loose anagen hair (MIM607721) shared the 4A>G missense change in SHOC2 (producing an S2G amino acid substitution) that introduces an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2S2G in vitro enhanced MAPK activation in a cell type–specific fashion. Induction of SHOC2S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype previously associated with aberrant signaling. These results document the first example of an acquired N-terminal lipid modification of a protein causing human disease.


Journal of Immunology | 2012

Immune Surveillance Properties of Human NK Cell-Derived Exosomes

Luana Lugini; Serena Cecchetti; Veronica Huber; Francesca Luciani; Gianfranco Macchia; Francesca Spadaro; Luisa Paris; Laura Abalsamo; Marisa Colone; Agnese Molinari; Franca Podo; Licia Rivoltini; Carlo Ramoni; Stefano Fais

Exosomes are nanovesicles released by normal and tumor cells, which are detectable in cell culture supernatant and human biological fluids, such as plasma. Functions of exosomes released by “normal” cells are not well understood. In fact, several studies have been carried out on exosomes derived from hematopoietic cells, but very little is known about NK cell exosomes, despite the importance of these cells in innate and adaptive immunity. In this paper, we report that resting and activated NK cells, freshly isolated from blood of healthy donors, release exosomes expressing typical protein markers of NK cells and containing killer proteins (i.e., Fas ligand and perforin molecules). These nanovesicles display cytotoxic activity against several tumor cell lines and activated, but not resting, immune cells. We also show that NK-derived exosomes undergo uptake by tumor target cells but not by resting PBMC. Exosomes purified from plasma of healthy donors express NK cell markers, including CD56+ and perforin, and exert cytotoxic activity against different human tumor target cells and activated immune cells as well. The results of this study propose an important role of NK cell-derived exosomes in immune surveillance and homeostasis. Moreover, this study supports the use of exosomes as an almost perfect example of biomimetic nanovesicles possibly useful in future therapeutic approaches against various diseases, including tumors.


Cancer Research | 2008

Phosphatidylcholine-Specific Phospholipase C Activation in Epithelial Ovarian Cancer Cells

Francesca Spadaro; Carlo Ramoni; Delia Mezzanzanica; Silvia Miotti; Paola Alberti; Serena Cecchetti; Egidio Iorio; Vincenza Dolo; Silvana Canevari; Franca Podo

Elucidation of the mechanisms responsible for aberrant phosphatidylcholine (PC) metabolism in cancer cells may allow identification of novel biomarkers of tumor progression and design of new targeted anticancer therapies. We recently reported up-regulation of PC-specific phospholipases in epithelial ovarian cancer cells (EOC) compared with nontumoral (normal or immortalized) counterparts (EONT). In the present study, we focused, in the same cell systems, on levels, subcellular localization, and activity of PC-specific phospholipase C (PC-PLC), for which a key role in cell proliferation, differentiation, and apoptosis has been shown in several mammalian cells. A 66-kDa PC-PLC isoform, detected in nuclear and cytoplasmic compartments of both EOC and EONT cells, accumulated on the external plasma membrane of cancer cells only, where it colocalized with beta1 integrin, in nonraft membrane domains. PC-PLC activity was 3-fold higher in total cell lysates and 5-fold higher in membrane-enriched fractions of EOC compared with EONT cells. Serum deprivation induced in EOC, but not in EONT, cells a 3-fold decrease in PC-PLC activity, associated with a 40% drop in S-phase fraction. The recovery of both variables to their original levels in serum-restimulated (or lysophosphatidic acid-restimulated) EOC cells was strongly delayed, for at least 24 h, in the presence of the PC-PLC inhibitor tricyclodecan-9-yl-potassium xanthate (D609). The S-phase of serum-restimulated EONT cells was not sensitive to D609. These findings warrant further investigations on the role of PC-PLC and on the effects of its inhibition on the pathways responsible for constitutive EOC cell stimulation and cell proliferation.


Human Molecular Genetics | 2014

Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis

Elisabetta Flex; Mamta Jaiswal; Francesca Pantaleoni; Simone Martinelli; Marion Strullu; Eyad Kalawy Fansa; Aurélie Caye; Alessandro De Luca; Francesca Lepri; Radovan Dvorsky; Luca Pannone; Stefano Paolacci; Si Cai Zhang; Valentina Fodale; Gianfranco Bocchinfuso; Cesare Rossi; Emma M M Burkitt-Wright; Andrea Farrotti; Emilia Stellacci; Serena Cecchetti; Rosangela Ferese; Lisabianca Bottero; Silvana Castro; Odile Fenneteau; Benoît Brethon; Massimo Sanchez; Amy E. Roberts; Helger G. Yntema; Ineke van der Burgt; Paola Cianci

RASopathies, a family of disorders characterized by cardiac defects, defective growth, facial dysmorphism, variable cognitive deficits and predisposition to certain malignancies, are caused by constitutional dysregulation of RAS signalling predominantly through the RAF/MEK/ERK (MAPK) cascade. We report on two germline mutations (p.Gly39dup and p.Val55Met) in RRAS, a gene encoding a small monomeric GTPase controlling cell adhesion, spreading and migration, underlying a rare (2 subjects among 504 individuals analysed) and variable phenotype with features partially overlapping Noonan syndrome, the most common RASopathy. We also identified somatic RRAS mutations (p.Gly39dup and p.Gln87Leu) in 2 of 110 cases of non-syndromic juvenile myelomonocytic leukaemia, a childhood myeloproliferative/myelodysplastic disease caused by upregulated RAS signalling, defining an atypical form of this haematological disorder rapidly progressing to acute myeloid leukaemia. Two of the three identified mutations affected known oncogenic hotspots of RAS genes and conferred variably enhanced RRAS function and stimulus-dependent MAPK activation. Expression of an RRAS mutant homolog in Caenorhabditis elegans enhanced RAS signalling and engendered protruding vulva, a phenotype previously linked to the RASopathy-causing SHOC2S2G mutant. Overall, these findings provide evidence of a functional link between RRAS and MAPK signalling and reveal an unpredicted role of enhanced RRAS function in human disease.


Evidence-based Complementary and Alternative Medicine | 2014

Effects of Mentha suaveolens Essential Oil Alone or in Combination with Other Drugs in Candida albicans

Annarita Stringaro; Elisabetta Vavala; Marisa Colone; Federico Pepi; Giuseppina Mignogna; Stefania Garzoli; Serena Cecchetti; Rino Ragno; Letizia Angiolella

Candidosis is the most important cause of fungal infections in humans. The yeast Candida albicans can form biofilms, and it is known that microbial biofilms play an important role in human diseases and are very difficult to treat. The prolonged treatment with drugs has often resulted in failure and resistance. Due to the emergence of multidrug resistance, alternatives to conventional antimicrobial therapy are needed. This study aims to analyse the effects induced by essential oil of Mentha suaveolens Ehrh (EOMS) on Candida albicans and its potential synergism when used in combination with conventional drugs. Morphological differences between control and EOMS treated yeast cells or biofilms were observed by scanning electron microscopy and transmission electron microscopy (SEM and TEM resp.,). In order to reveal the presence of cell cycle alterations, flow cytometry analysis was carried out as well. The synergic action of EOMS was studied with the checkerboard method, and the cellular damage induced by different treatments was analysed by TEM. The results obtained have demonstrated both the effects of EOMS on C. albicans yeast cells and biofilms and the synergism of EOMS when used in combination with conventional antifungal drugs as fluconazole (FLC) and micafungin (MCFG), and therefore we can hypothesize on its potential use in therapy. Further studies are necessary to know its mechanism of action.


Breast Cancer Research | 2010

Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells

Luisa Paris; Serena Cecchetti; Francesca Spadaro; Laura Abalsamo; Luana Lugini; Maria Elena Pisanu; Egidio Iorio; Pier Giorgio Natali; Carlo Ramoni; Franca Podo

IntroductionOverexpression on plasma membrane of human epidermal growth factor receptor 2 (HER2) is reported in 25% to 30% of breast cancers. Heterodimer formation with cognate members of the epidermal growth factor receptor (EGFR) family, such as HER3 and EGFR, activates abnormal cell-signalling cascades responsible for tumorigenesis and further transcriptional HER2 gene upregulation. Targeting the molecular mechanisms controlling HER2 overexpression and recycling may effectively deactivate this feedback-amplification loop. We recently showed that inactivation of phosphatidylcholine-specific phospholipase C (PC-PLC) may exert a pivotal role in selectively modulating the expression on the membrane of specific receptors or proteins relevant to cell function. In the present study, we investigated the capability of PC-PLC inhibition to target the molecular mechanisms controlling HER2 overexpression on the membrane of breast cancer cells by altering the rates of its endocytosis and lysosomal degradation.MethodsLocalization on the membrane and interaction of PC-PLC with HER2, EGFR, and HER3 were investigated on HER2-overexpressing and HER2-low breast cancer cell lines, by using confocal laser scanning microscopy, flow cytometry, cell-surface biotinylation, isolation of lipid rafts, and immunoprecipitation experiments. The effects of the PC-PLC inhibitor tricyclodecan-9-yl-potassium xanthate (D609) on HER2 expression on the membrane and on the levels of overall HER2, HER2-HER3, and HER2-EGFR contents were monitored in the HER2-overexpressing SKBr3 cells, after either transient or continuous receptor engagement with anti-HER2 monoclonal antibodies, including trastuzumab. Changes of HER2 expression and cell proliferation were examined in SKBr3, BT-474, and MDA-MB-453 cells continuously exposed to D609 alone or combined with trastuzumab.ResultsPC-PLC selectively accumulates on the plasma membrane of HER2-overexpressing cells, where it colocalizes and associates with HER2 in raft domains. PC-PLC inhibition resulted in enhanced HER2 internalization and lysosomal degradation, inducing downmodulation of HER2 expression on the membrane. Moreover, PC-PLC inhibition resulted in strong retardation of HER2 reexpression on the membrane and a decrease in the overall cellular contents of HER2, HER2-HER3, and HER2-EGFR heterodimers. The PC-PLC inhibitor also induced antiproliferative effects, especially in trastuzumab-resistant cells.ConclusionsThe results pointed to PC-PLC inhibition as a potential means to counteract the tumorigenic effects of HER2 amplification and complement the effectiveness of current HER2-targeting therapies.


Blood | 2008

Phosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB–driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages

Laura Fantuzzi; Francesca Spadaro; Cristina Purificato; Serena Cecchetti; Franca Podo; Filippo Belardelli; Sandra Gessani; Carlo Ramoni

CCL2 (MCP-1) has been shown to enhance HIV-1 replication. The expression of this chemokine by macrophages is up-modulated as a consequence of viral infection or gp120 exposure. In this study, we show for the first time that the phosphatidylcholine-specific phospholipase C (PC-PLC) is required for the production of CCL2 triggered by gp120 in human monocyte-derived macrophages (MDMs). Using a combination of pharmacologic inhibition, confocal laser-scanner microscopy, and enzymatic activity assay, we demonstrate that R5 gp120 interaction with CCR5 activates PC-PLC, as assessed by a time-dependent modification of its subcellular distribution and a concentration-dependent increase of its enzymatic activity. Furthermore, PC-PLC is required for NF-kB-mediated CCL2 production triggered by R5 gp120. Notably, PC-PLC activation through CCR5 is specifically induced by gp120, since triggering CCR5 through its natural ligand CCL4 (MIP-1beta) does not affect PC-PLC cellular distribution and enzymatic activity, as well as CCL2 secretion, thus suggesting that different signaling pathways can be activated through CCR5 interaction with HIV-1 or chemokine ligands. The identification of PC-PLC as a critical mediator of well-defined gp120-mediated effects in MDMs unravels a novel mechanism involved in bystander activation and may contribute to define potential therapeutic targets to block Env-triggered pathologic responses.


American Journal of Human Genetics | 2015

Mutations Impairing GSK3-Mediated MAF Phosphorylation Cause Cataract, Deafness, Intellectual Disability, Seizures, and a Down Syndrome-like Facies

Marcello Niceta; Emilia Stellacci; Karen W. Gripp; Giuseppe Zampino; Maria Kousi; Massimiliano Anselmi; Alice Traversa; Andrea Ciolfi; Deborah L. Stabley; Alessandro Bruselles; Viviana Caputo; Serena Cecchetti; Sabrina Prudente; Maria Teresa Fiorenza; Carla Boitani; Nicole Philip; Dmitriy Niyazov; Chiara Leoni; Takaya Nakane; Kim M. Keppler-Noreuil; Stephen R. Braddock; Gabriele Gillessen-Kaesbach; Antonio Palleschi; Philippe M. Campeau; Brendan Lee; Celio Pouponnot; Lorenzo Stella; Gianfranco Bocchinfuso; Nicholas Katsanis; Katia Sol-Church

Transcription factors operate in developmental processes to mediate inductive events and cell competence, and perturbation of their function or regulation can dramatically affect morphogenesis, organogenesis, and growth. We report that a narrow spectrum of amino-acid substitutions within the transactivation domain of the v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a leucine zipper-containing transcription factor of the AP1 superfamily, profoundly affect development. Seven different de novo missense mutations involving conserved residues of the four GSK3 phosphorylation motifs were identified in eight unrelated individuals. The distinctive clinical phenotype, for which we propose the eponym Aymé-Gripp syndrome, is not limited to lens and eye defects as previously reported for MAF/Maf loss of function but includes sensorineural deafness, intellectual disability, seizures, brachycephaly, distinctive flat facial appearance, skeletal anomalies, mammary gland hypoplasia, and reduced growth. Disease-causing mutations were demonstrated to impair proper MAF phosphorylation, ubiquitination and proteasomal degradation, perturbed gene expression in primary skin fibroblasts, and induced neurodevelopmental defects in an in vivo model. Our findings nosologically and clinically delineate a previously poorly understood recognizable multisystem disorder, provide evidence for MAF governing a wider range of developmental programs than previously appreciated, and describe a novel instance of protein dosage effect severely perturbing development.


Nature Genetics | 2014

Mutations in ZBTB20 cause Primrose syndrome

Viviana Cordeddu; Bert Redeker; Emilia Stellacci; Aldo Jongejan; Alessandra Fragale; Ted E.J. Bradley; Massimiliano Anselmi; Andrea Ciolfi; Serena Cecchetti; Valentina Muto; Laura Bernardini; Meron Azage; Daniel R. Carvalho; Alberto J. Espay; Alison Male; Anna Maja Molin; Renata Posmyk; Carla Battisti; Alberto Casertano; Daniela Melis; Antoine H. C. van Kampen; Frank Baas; Marcel Mannens; Gianfranco Bocchinfuso; Lorenzo Stella; Marco Tartaglia; Raoul C. M. Hennekam

Primrose syndrome and 3q13.31 microdeletion syndrome are clinically related disorders characterized by tall stature, macrocephaly, intellectual disability, disturbed behavior and unusual facial features, with diabetes, deafness, progressive muscle wasting and ectopic calcifications specifically occurring in the former. We report that missense mutations in ZBTB20, residing within the 3q13.31 microdeletion syndrome critical region, underlie Primrose syndrome. This finding establishes a genetic link between these disorders and delineates the impact of ZBTB20 dysregulation on development, growth and metabolism.


European Journal of Immunology | 2007

Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells

Serena Cecchetti; Francesca Spadaro; Luana Lugini; Franca Podo; Carlo Ramoni

CD16, the low‐affinity FcIgG receptor (FcγRIIIA), is predominantly expressed in human NK cells. Our recent findings indicate that CD16 expression on the outer membrane surface of NK cells is correlated with the membrane expression of phosphatidylcholine‐specific phospholipase C (PC‐PLC). In the present study we analyzed the trafficking of CD16 from the plasma membrane to cytoplasmic regions, after stimulation with specific mAb. The CD16 receptor is internalized, likely degraded and newly synthesized; its endocytosis is independent of ATP, but requires an integral and functional actin cytoskeleton. Antibody‐mediated CD16 cross‐linking results in an approximately twofold increase in PC‐PLC enzymatic activity within 10 min. Analysis of PC‐PLC and CD16 distribution in NK cell plasma membrane demonstrates that the proteins are physically associated and partially accumulated in lipid rafts. Pre‐incubation of NK cells with a PC‐PLC inhibitor, D609, causes a dramatic decrease both in CD16 receptor and PC‐PLC enzyme expression on the plasma membrane. Interestingly, among phenotype PBL markers, only CD16 is strongly down‐modulated by D609 treatment. CD16‐mediated cytotoxicity is also reduced after D609 incubation. Taken together, these data suggest that the PC‐PLC enzyme could play an important role in regulating CD16 membrane expression, the CD16‐mediated cytolytic mechanism and CD16‐triggered signal transduction.

Collaboration


Dive into the Serena Cecchetti's collaboration.

Top Co-Authors

Avatar

Franca Podo

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Francesca Spadaro

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Carlo Ramoni

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Egidio Iorio

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Giulia Carpinelli

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Luana Lugini

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Alessandro Ricci

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Marco Lalle

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Rossella Canese

Istituto Superiore di Sanità

View shared research outputs
Top Co-Authors

Avatar

Marco Tartaglia

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge